journal article·2024-12Open access

LncRNA evf‐2 Exacerbates Podocyte Injury in Diabetic Nephropathy by Inducing Cell Cycle Re‐entry and Inflammation Through Distinct Mechanisms Triggered by hnRNPU

Chaojie Zhang, Hui Zhao, Yufan Yan, Yanfei Li, Min Lei, Yong Liu, Longhua Yang, Huijian Zhao, Sijie Zhou, Shaokang Pan, Zhangsuo Liu, Jia Guo

Advanced Science· Volume 11· Issue 47

Abstract

Abstract Albuminuria is a hallmark of diabetic nephropathy (DN). Podocyte injury significantly contributes to proteinuria in DN. Our study found that lncRNA EVF‐2 is upregulated in podocytes of DN patients, correlating with cell cycle re‐entry and inflammation. Specific knockout or knockdown of lncRNA evf‐2 in diabetic mice or cultured podocytes alleviated podocyte injury associated with these processes. RNA sequencing of evf‐2‐overexpressing podocytes unveiled a predominant enrichment of upregulated mRNAs in cell cycle and inflammation pathways, with alternative splicing in cell cycle‐related mRNAs Ccnb1 and Tacc3. Chromatin isolation by RNA purification‐mass spectrometry (ChIRP‐MS) analysis highlighted the involvement of ribonucleoprotein complex and mRNA processing‐related proteins, with hnRNPU as the main binding partner of evf‐2 in spliceosomes. Knockdown of hnRNPU partially restored the upregulation of mRNAs induced by evf‐2 overexpression, altering splice variants of Ccnb1 and Tacc3. This study is the first to reveal the splice variants of cell cycle‐related genes in DN and elucidate the interaction between lncRNA evf‐2 and hnRNPU. This interaction culminates in the upregulation of cell cycle‐related genes and inflammatory factors through diverse pathways, potentially involving transcriptional activation, RNA stability modulation, alternative splicing or translational regulation. This highlights potential novel pathways for DN treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · Lipid metabolism and disorders · RNA Research and Splicing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nephrology Research Center the First Affiliated Hospital of Zhengzhou University Zhengzhou 450052 P. R. China

Henan Province Research Center for Kidney Disease Zhengzhou 450052 P. R. China

Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province Zhengzhou 450052 P. R. China

School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies Zhengzhou University Henan 450001 China

Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences Zhengzhou University Zhengzhou Henan 450001 China

Innovation Center of Basic Research for Metabolic‐Associated Fatty Liver Disease Ministry of Education of China China

Funding

National Natural Science Foundation of China

References (49)

Show source-provided references
1. 10.1056/NEJMc160246910.1056/NEJMc1602469 ↗
2. 10.1080/14728222.2019.162472110.1080/14728222.2019.1624721 ↗
3. 10.1016/j.tem.2016.07.00210.1016/j.tem.2016.07.002 ↗
4. 10.3390/ijms2124945610.3390/ijms21249456 ↗
5. 10.1172/JCI7227110.1172/JCI72271 ↗
6. 10.1016/j.kint.2019.05.01510.1016/j.kint.2019.05.015 ↗
7. Deng B. · Int. J. Mol. Sci. · 2023 · 24
8. 10.1159/00049327810.1159/000493278 ↗
9. 10.1038/s41419-020-2630-x10.1038/s41419-020-2630-x ↗
10. 10.1016/j.kint.2022.10.03010.1016/j.kint.2022.10.030 ↗
11. 10.1038/s41581-024-00827-z10.1038/s41581-024-00827-z ↗
12. 10.1093/bib/bbv03110.1093/bib/bbv031 ↗
13. 10.1016/j.tibs.2018.09.01210.1016/j.tibs.2018.09.012 ↗
14. 10.1016/j.tig.2015.03.00710.1016/j.tig.2015.03.007 ↗
15. 10.1016/j.cell.2018.01.01110.1016/j.cell.2018.01.011 ↗
16. 10.1038/s41419-023-05695-210.1038/s41419-023-05695-2 ↗
17. 10.1016/j.molcel.2018.07.02410.1016/j.molcel.2018.07.024 ↗
18. 10.1101/gad.141610610.1101/gad.1416106 ↗
19. Shamovsky I. · Gene Control by Large Noncoding RNAs. Sci. STKE · 2006 · 355 · pe40
20. 10.1007/s00439-016-1683-510.1007/s00439-016-1683-5 ↗
21. 10.1016/j.semcdb.2018.07.00610.1016/j.semcdb.2018.07.006 ↗
22. 10.1038/s41467-018-08235-110.1038/s41467-018-08235-1 ↗
23. 10.1002/dmrr.355610.1002/dmrr.3556 ↗
24. 10.1016/j.molcel.2019.02.00210.1016/j.molcel.2019.02.002 ↗
25. 10.1016/j.metabol.2022.15515510.1016/j.metabol.2022.155155 ↗
26. 10.1038/s12276-019-0259-610.1038/s12276-019-0259-6 ↗
27. 10.2174/15665241380448625010.2174/156652413804486250 ↗
28. 10.1016/j.ajpath.2013.06.03310.1016/j.ajpath.2013.06.033 ↗
29. 10.1016/j.kint.2022.04.02710.1016/j.kint.2022.04.027 ↗
30. 10.7150/ijbs.6223810.7150/ijbs.62238 ↗
31. 10.1016/j.kint.2021.08.02610.1016/j.kint.2021.08.026 ↗
32. 10.1038/s41419-023-05658-710.1038/s41419-023-05658-7 ↗
33. 10.3389/fphar.2021.64765010.3389/fphar.2021.647650 ↗
34. 10.1089/ars.2021.022710.1089/ars.2021.0227 ↗
35. 10.1042/CS2019037210.1042/CS20190372 ↗
36. 10.1101/cshperspect.a03215110.1101/cshperspect.a032151 ↗
37. Zhang R.‐M. · Biochem. Biophys. Res. Commun. · 2018 · 507
38. 10.1016/j.ejphar.2019.17277810.1016/j.ejphar.2019.172778 ↗
39. 10.1089/cbr.2019.296010.1089/cbr.2019.2960 ↗
40. 10.1038/s12276-023-01010-310.1038/s12276-023-01010-3 ↗
41. 10.2337/db21-114510.2337/db21-1145 ↗
42. 10.1080/15384101.2024.230224310.1080/15384101.2024.2302243 ↗
43. 10.1158/0008-5472.CAN-23-281210.1158/0008-5472.CAN-23-2812 ↗
44. 10.1016/j.drup.2020.10072810.1016/j.drup.2020.100728 ↗
45. National Research Council Institute for Laboratory Animal · 1996
46. 10.1038/s41586-021-03819-210.1038/s41586-021-03819-2 ↗
47. 10.1093/nar/gkab106110.1093/nar/gkab1061 ↗
48. 10.1093/nar/gkac105210.1093/nar/gkac1052 ↗
49. 10.1016/j.cell.2017.05.02910.1016/j.cell.2017.05.029 ↗